logo
Introduction
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase
The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials
The role of immunologic and viral markers in predicting clinical outcome in HIV infection
Clinical significance of drug resistance in HIV-1 infection